SCHEMBL4428365

SCHEMBL4428365

NCCCN1C(=O)CCC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
HTR2A P28223 1/20 0.44
FAAH O00519 1/20 0.43
MGLL Q99685 1/20 0.43
HEXA P06865 2/20 0.40
HEXB P07686 2/20 0.40
MAPT P10636 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA9 Q16790 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 1/20 0.34
HTR1A P08908 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL12501659 0.98 MEN1 (0.42) MEN1KMT2APOLBHTR2AFAAH
SCHEMBL22394483 0.93 FAAH (0.46) MEN1KMT2APOLBHTR2AFAAH
SCHEMBL7229004 0.91 MEN1 (0.55) MEN1KMT2APOLBHTR2AFAAH
SCHEMBL2907080 0.91 FAAH (0.44) MEN1KMT2APOLBHTR2AFAAH
SCHEMBL6565273 0.91 FAAH (0.44) MEN1KMT2APOLBHTR2AFAAH
Hydrochloric Acid SCHEMBL12501634 0.89 MEN1 (0.53) MEN1KMT2APOLBHTR2AFAAH
SCHEMBL1108307 0.84 CA1 (0.41) MEN1KMT2APOLBFAAHMGLL
SCHEMBL8829446 0.84 FAAH (0.53) MEN1KMT2APOLBFAAHMGLL
SCHEMBL888672 0.84 MEN1 (0.50) MEN1KMT2APOLBFAAHMGLL
SCHEMBL31065451 0.82 MEN1 (0.52) MEN1KMT2APOLBHTR2AFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3962491-B1 INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES UNIV SANTIAGO COMPOSTELA (ES) 2025-08-06 EP disclosed
CN-118667066-A Polymer, preparation method, binder, positive electrode sheet, secondary battery and electricity utilization device 宁德时代新能源科技股份有限公司 2024-09-20 CN disclosed
US-20220177603-A1 INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) 2022-06-09 US disclosed
US-20220071917-A9 DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) 2022-03-10 US disclosed
EP-3962491-A1 INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES Universidade De Santiago De Compostela (ES) 2022-03-09 EP disclosed
CN-113825515-A Intracellular delivery of anti-KRAS antibodies formulated as nanocapsules 圣地亚哥德孔波斯特拉大学 2021-12-21 CN disclosed
US-20210228494-A1 DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) 2021-07-29 US disclosed
WO-2020221849-A1 INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) 2020-11-05 WO disclosed
EP-3703666-A1 DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS Universidade de Santiago de Compostela (ES) 2020-09-09 EP disclosed
CN-107266681-A Amine polymer as bile acid sequestrant 瑞立普萨公司 2017-10-20 CN disclosed
CN-102906159-B Amine polymers as bile acid sequestrants 瑞立普萨公司 2017-09-26 CN disclosed
US-20130012485-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-01-10 US disclosed
US-20110217311-A1 CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-09-08 US disclosed
EP-2124913-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS Novartis AG (CH) 2009-12-02 EP disclosed
US-7470703-B1 Yohimbine derivatives and use thereof THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2008-12-30 US disclosed
US-7470703-B1 Yohimbine derivatives and use thereof THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2008-12-30 US disclosed
WO-2008077597-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS NOVARTIS AG (CH) 2008-07-03 WO disclosed
WO-2006129100-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-12-07 WO disclosed
WO-2003053958-A1 QUINAZOLINEDIONE DERIVATIVES CELLTECH R & D LIMITED (GB) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210228494-A1 DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS LNPEP, CLIC1, CLSPN MEN1 2022/4885KMT2A 2142/4885POLB 4737/4885
US-20110217311-A1 CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DTYMK, CMPK1, UCK2 MEN1 1590/4885KMT2A 1239/4885POLB 226/4885
US-20130012485-A1 ORGANIC COMPOUNDS DPP4, DPP3, DPP7 MEN1 2669/4885KMT2A 2558/4885POLB 2463/4885
US-20220071917-A9 DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS LNPEP, CLIC1, CLSPN MEN1 2022/4885KMT2A 2142/4885POLB 4737/4885
US-20220177603-A1 INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES KRAS, NRAS, TP53 MEN1 1457/4885KMT2A 3294/4885POLB 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.